Ascendis Pharma A/S (ASND) vs BridgeBio Pharma, Inc. (BBIO)
Ascendis Pharma A/S and BridgeBio Pharma, Inc. are both Biotechnology companies. Ascendis Pharma A/S is the larger, with a market value of $15.7B against $13.1B — 1.2× the size. BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Ascendis Pharma A/S trades at 16.3×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 126.0%. Ascendis Pharma A/S has the higher net margin (71.2% vs −97.0%) and the higher return on invested capital (15.1% vs 0.00%). Across the 17 metrics below, Ascendis Pharma A/S leads on 13 and BridgeBio Pharma, Inc. on 4.
Valuation
Profitability
| Metric | ASND | BBIO | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.26% | 94.44% | 65.16% |
| Operating margin | 24.84% | (69.81%) | 0.00% |
| Net margin | 71.20% | (97.03%) | 0.00% |
| Free cash flow margin | 31.97% | (61.06%) | 0.00% |
| Return on equity | 118.44% | 32.31% | (57.72%) |
| Return on assets | 44.34% | (60.23%) | (49.22%) |
| Return on invested capital | 15.07% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack